⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ORIC News
Oric Pharmaceuticals, Inc. Common Stock
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
globenewswire.com
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ORIC
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com
ORIC
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
prnewswire.com
ONCY
NRIX
ERAS
FHTX
ORIC
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
globenewswire.com
ORIC
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
ORIC
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
globenewswire.com
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ORIC
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
globenewswire.com
ORIC
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
globenewswire.com
ORIC